News

ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery

Round is co-led by EDBI, Anzu Partners and UTEC, representing major biotech innovation centers across the U.S., Singapore, and Japan
Download PDF

SINGAPORE and SAN DIEGO – April 14, 2021ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore. The new round brings ImmunoScape’s total funding in the past year to $25 million.

ImmunoScape will use the funding to enlarge its Singapore-based team, further its expansion into the U.S., and scale up its newly announced San Diego laboratory. The company will also be able to continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient’s immunome at ultra-high resolution. ImmunoScape will be working to increase its capacity for in-house R&D activities and to expand its partnerships with biopharma and leading academics in drug development efforts within immuno-oncology, infectious disease, and autoimmune disease.

 

“Since our last funding announcement less than a year ago, we have made significant strides in our collaborations with organizations such the NIAID and Johns Hopkins, with whom we published multiple COVID-19 studies, one of which was recently spotlighted by the NIH,” said Choon Peng Ng, CEO of ImmunoScape. “We also established a Scientific Advisory Board chaired by our co-founder, Evan Newell, and grown our U.S. presence with experienced scientists and biotech executives, like Geoff Nosrati, as our Chief Business Officer. This new financing will allow us deepen our relationships with partners in the development of next generation therapeutics.”

 

ImmunoScape’s Deep Immunomics platform integrates single-cell analysis technologies and cutting-edge bioinformatics for both drug discovery and high-dimensional immune profiling. For example, its TargetScape® technology can be used to detect rare antigen specific T-cells with frequencies as low as 1 in 100,000 CD8+ cells, and simultaneously provide comprehensive phenotypic information for these antigen specific T cells.

 

“ImmunoScape is a global company with a highly differentiated platform that can change the way lifesaving treatments are developed,” said David Michael, Managing Partner at Anzu Partners. “We are delighted to help bring this technology to biopharma leaders and support drug development in immuno-oncology and infectious disease.”

 

“Since the Series A financing led by UTEC, ImmunoScape has made remarkable progress. Their numerous collaborations with prominent academic institutions and biopharma companies have demonstrated that their proprietary immunomics platform can bring novel clinical insights to immune oncology and infectious diseases,” said Nori Kurokawa, Partner at UTEC. “UTEC is delighted to work with ImmunoScape, Anzu Partners and EDBI to transform clinical insights into novel immuno-therapies.”

 

To learn more about ImmunoScape please visit https://immunoscape.com/.

 

About ImmunoScape

ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. For more information, please visit https://immunoscape.com/.

 

About Anzu Partners

Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit https://anzupartners.com/.

 

 

About EDBI
Investing since 1991, EDBI is a Singapore-based global investor in select high growth technology sectors ranging from Information & Communication Technology (ICT), Emerging Technology (ET), Healthcare (HC) and promising Singapore SMEs in strategic industries. As a value creating investor, EDBI assists companies achieve their ambitious goals by leveraging our broad network, resources and expertise. With our growth capital, EDBI supports companies seeking to expand in Asia and globally through Singapore. For more information, please visit https://www.edbi.com.

 

 

About UTEC

UTEC is a seed/early-stage technology focused venture capital firm associated with academic institutes such as The University of Tokyo. UTEC supports the creation and growth of start-ups that vigorously foster business globally through the use of superior science and technology, collaborating with universities, research institutes and investment partners in and out of Japan. For more information, please visit https://www.ut-ec.co.jp/english/.

 

 

Media Contacts

Kalyn Schieffer for ImmunoScape and Anzu Partners

kos@anzupartners.com

 

 

 

 

Top